Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

human small cell lung cancer

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Small Interfering RNA (siRNA) (1) Tim3 (1) VISTA (1) ADC Antibody (3) ADC Payload (2) Akt (10) Anaplastic lymphoma kinase (ALK) (4) Antibody-Drug Conjugates (ADCs) (6) Apoptosis (26) Autophagy (13) Bacterial (1) Bcl-2 Family (1) c-Kit (2) c-Met/HGFR (4) CaMK (2) Caspase (5) CD276/B7-H3 (1) CD28 (1) CD3 (1) CDK (5) Checkpoint Kinase (Chk) (1) Complement System (1) CTLA-4 (1) CXCR (1) Discoidin Domain Receptor (1) DNA Alkylator/Crosslinker (1) DNA/RNA Synthesis (1) Drug Derivative (3) Drug Intermediate (3) E1/E2/E3 Enzyme (1) EGFR (16) Endogenous Metabolite (4) Epigenetic Reader Domain (1) ERK (10) Fat Mass and Obesity-associated Protein (FTO) (1) Ferroptosis (4) FGFR (1) Glutathione Peroxidase (1) Histone Acetyltransferase (1) Histone Demethylase (2) HIV (1) hnRNP (1) IFNAR (1) IGF-1R (1) Indoleamine 2,3-Dioxygenase (IDO) (1) Integrin (1) Interleukin Related (2) Isotope-Labeled Compounds (3) JNK (2) Keap1-Nrf2 (4) MEK (2) MetAP (1) Methionine Adenosyltransferase (MAT) (1) Microtubule/Tubulin (5) Mitophagy (3) mTOR (3) Na+/H+ Exchanger (NHE) (1) Necroptosis (1) NF-κB (2) Notch (5) Opioid Receptor (3) p38 MAPK (3) PARP (2) PD-1/PD-L1 (8) PI3K (4) PI5P4K (1) Pim (1) PINK1/Parkin (3) PKC (1) Prostaglandin Receptor (1) PROTACs (4) Proteasome (1) Pyroptosis (1) Pyruvate Kinase (1) Raf (2) Ras (1) Reactive Oxygen Species (ROS) (1) Reference Standards (5) ROS Kinase (1) Sodium Phosphate Cotransporter (1) Src (1) STAT (3) Survivin (3) SWI/SNF Complex (1) Syk (1) TGF-beta/Smad (2) TNF Receptor (3) Toll-like Receptor (TLR) (2) Topoisomerase (3) Transmembrane Glycoprotein (4) Trk Receptor (1) TROP2 (1) TRP Channel (3) TrxR (1) VEGFR (4) Wee1 (2) Wnt (3) β-catenin (2)
By Research Areas:	Cancer (113) Cardiovascular Disease (1) Endocrinology (1) Infection (4) Inflammation/Immunology (15) Metabolic Disease (1) Neurological Disease (4)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	CpG ODNs (1)

115

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

MCE Kits

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

GMP Molecules

Luteolin Maximum Cited Publications 89 Publications Verification Luteoline; Luteolol; Digitoflavone	Keap1-Nrf2 Apoptosis Autophagy Endogenous Metabolite	Inflammation/Immunology Cancer
Luteolin (Luteoline), a flavanoid compound, is a potent Nrf2 inhibitor. Luteolin has anti-inflammatory, anti-cancer properties, including the induction of apoptosis and cell cycle arrest, and the inhibition of metastasis and angiogenesis, in several cancer cell lines, including human non-small lung cancer cells .

Erlotinib 130+ Cited Publications CP-358774; NSC 718781; OSI-774	EGFR Autophagy	Cancer
Erlotinib (CP-358774) is a directly acting EGFR tyrosine kinase inhibitor, with an IC₅₀ of 2 nM for human EGFR. Erlotinib reduces EGFR autophosphorylation in intact tumor cells with an IC₅₀ of 20 nM. Erlotinib is used for the treatment of non-small cell lung cancer . Erlotinib is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Nivolumab Maximum Cited Publications 23 Publications Verification BMS-936558; ONO-4538; MDX-1106	PD-1/PD-L1	Infection Cancer
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

Tarlatamab 1 Publications Verification AMG-757	Notch	Inflammation/Immunology Cancer
Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the K_Ds of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the K_Ds of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research .

Datopotamab deruxtecan (solution) 2 Publications Verification DS-1062 (solution); Dato-DXd (solution)	TROP2 Antibody-Drug Conjugates (ADCs) Topoisomerase	Cancer
Datopotamab deruxtecan (DS-1062) solution is a TROP2-targeted antibody-drug conjugate (ADC) with human TROP2 K_d of 0.74 nmol/L. Datopotamab deruxtecan solution consists of the antibody Datopotamab (HY-P99843) and the toxic molecule-linker conjugate Deruxtecan (HY-13631E). Datopotamab deruxtecan solution binds TROP2, triggers internalization and lysosomal trafficking and releases DXd topoisomerase I inhibitor payload. Datopotamab deruxtecan solution disrupts DNA function, induces DNA damage, apoptosis, and bystander killing of tumor microenvironment cells. Datopotamab deruxtecan solution can be used in research related to triple-negative breast cancer, gastric cancer, and non-small cell lung cancer .

Matrine 15+ Cited Publications Matridin-15-one; Vegard; α-Matrine	PINK1/Parkin Opioid Receptor Autophagy Mitophagy Ferroptosis Apoptosis	Inflammation/Immunology Cancer
Matrine (Matridin-15-one) is an alkaloid found in plants from the Sophora genus that can act as a kappa opioid receptor and u-receptor agonist. Matrine has a variety of pharmacological effects, including anti-cancer, anti-oxidative stress, anti-inflammation and anti-apoptosis effects. Matrine is potential in the research of disease like human non-small cell lung cancer, hepatoma, papillary thyroid cancer and acute kidney injury (AKI) .

Patritumab 1 Publications Verification AMG-888; U3-1287	EGFR Akt ERK PARP Survivin	Cancer
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .

HLX43	Antibody-Drug Conjugates (ADCs) PD-1/PD-L1	Cancer
HLX43 is an antibody-drug conjugate (ADC) targeting PD-L1. HLX43 consists of a human monoclonal antibody anti-PD-L1 antibody Opucolimab (HY-P99785) with the drug-linker conjugate being DL-01 (HY-155870A). HLX43 exerts superior anticancer efficacy with safety profile in vivo. HLX43 can be used for non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), esophageal squamous cell carcinoma (ESCC), melanoma (MEL), ovarian cancer (Ovc) research .

Necitumumab 11F8; IMC-11F8; LY3012211	EGFR	Cancer
Necitumumab (11F8; IMC-11F8; LY3012211) is a human IgG monoclonal antibody directed against EGFR. Necitumumab binds to the EGF binding site of EGFR, blocks ligand binding, neutralizes ligand-induced EGFR phosphorylation and downstream signaling, induces EGFR internalization and degradation, and mediates antibody-dependent cellular cytotoxicity (ADCC) in EGFR-expressing cells. Necitumumab enhances antitumour activity in combination with Gemcitabine (HY-17026) and Cisplatin (HY-17394) in murine non-small-cell lung cancer xenograft models. Necitumumab can be used in research on cancers such as non-small cell lung cancer and colorectal cancer .

(αR)-Cyclopropaneacetamide-Exatecan SHR169265	ADC Payload Topoisomerase	Cancer
(αR)-Cyclopropaneacetamide-Exatecan (SHR169265) is a DNA Topoisomerase I inhibitor with enhanced membrane permeability (with an IC₅₀ of 1.34 μM against the human DNA Topoisomerase I). (αR)-Cyclopropaneacetamide-Exatecan exerts cytotoxic effects by inhibiting the enzymatic activity of Topoisomerase I, and this anticancer effect is independent of the expression level of HER2. (αR)-Cyclopropaneacetamide-Exatecan is an ADC Cytotoxin derived from Exatecan (HY-13631), which can be used in research related to advanced cancers such as breast cancer, gastric cancer, colorectal cancer and non-small cell lung cancer .

Obrixtamig BI 764532; OBT 620	CD3	Cancer
Obrixtamig (BI 764532; OBT 620) is an CD3E/DLL3-targeting L-κ-G1-h-CH2-CH3_L-λ-G1-h-CH2-CH3 type human antibody. Obrixtamig is a delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager. Obrixtamig can be used for research of DLL3-positive small cell lung cancer .

FZ-AD005	Antibody-Drug Conjugates (ADCs) Topoisomerase Apoptosis	Cancer
FZ-AD005 is a DLL3-targeting antibody-drug conjugate (ADC) with high selectivity, composed of the anti-DLL3 antibody FZ-A038 (HY-P990896), a dipeptide linker (Val-Ala), and DXd (HY-13631D). The K_d value of FZ-AD005 for human DLL3 ranges from 13.29 to 58.3 pmol/L. After binding to DLL3 on the cell surface, FZ-AD005 mediates endocytosis, and the payload DXd is released via cleavage by lysosomal cathepsins. DXd inhibits topoisomerase TopI to induce double-strand DNA breaks, cell cycle arrest and apoptosis, and FZ-AD005 exhibits bystander killing activity against adjacent DLL3-negative cells. FZ-AD005 shows stable circulation in vivo, has good tolerance and acceptable pharmacokinetic profiles in rats and cynomolgus monkeys, and effectively inhibits the growth of DLL3-expressing tumor cells. FZ-AD005 serves as a promising candidate molecule for research on small cell lung cancer and human neuroendocrine prostate cancer .

Ralimetinib 10+ Cited Publications LY2228820	p38 MAPK Autophagy	Cancer
Ralimetinib is an ATP-competitive p38α and p38β MAPK inhibitor with an IC₅₀ of 5.3 nmol/L against human p38α and an IC₅₀ of 3.2 nmol/L against human p38β. Ralimetinib slows tumor growth in preclinical in vivo cancer models, exhibits oral bioavailability in mice, and achieves sustained target inhibition for 4 to 8 h. Ralimetinib is applicable for research on melanoma, non-small cell lung cancer, ovarian cancer, glioma, multiple myeloma, breast cancer, renal cancer, and head and neck squamous cell carcinoma .

Cucurbitacin IIa 1 Publications Verification Hemslecin A	Survivin Apoptosis EGFR Caspase p38 MAPK Autophagy MEK Raf ERK STAT CaMK	Inflammation/Immunology Cancer
Cucurbitacin IIa (Hemslecin A) is an orally active, blood-brain barrier-permeable EGFR inhibitor with an IC₅₀ of 1.455 nM against human EGFR. Cucurbitacin IIa induces caspase-3-dependent apoptosis, downregulates survivin expression, enhances autophagy levels, disrupts the actin cytoskeleton via actin aggregation, arrests the cell cycle at the G2/M phase, and exerts anti-inflammatory activity by inhibiting the EGFR-MAPK signaling pathway. Cucurbitacin IIa can be used in the research of inflammation-related diseases, depression, and cancers such as non-small cell lung cancer .

Cixutumumab IMC-A12; NSC742460	IGF-1R	Cancer
Cixutumumab (IMC-A12) is a human anti-IGF-1R monoclonal antibody with high affinity that inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab also mediates the internalization and degradation of IGF-IR. Cixutumumab shows broad-spectrum anti-tumour activity and can be used in studies of cancers such as lung cancer, malignancies, leukaemia, non-small cell lung cancer and prostate cancer .

Erlotinib (Standard) CP-358774 (Standard); NSC 718781 (Standard); OSI-774 (Standard)	Reference Standards EGFR Autophagy	Cancer
Erlotinib (Standard) is the analytical standard of Erlotinib. This product is intended for research and analytical applications. Erlotinib (CP-358774) is a directly acting EGFR tyrosine kinase inhibitor, with an IC₅₀ of 2 nM for human EGFR. Erlotinib reduces EGFR autophosphorylation in intact tumor cells with an IC₅₀ of 20 nM. Erlotinib is used for the treatment of non-small cell lung cancer . Erlotinib is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Luteolin (Standard) Maximum Cited Publications 89 Publications Verification Luteoline(Standard); Luteolol(Standard); Digitoflavone (Standard)	Reference Standards Keap1-Nrf2 Apoptosis Autophagy Endogenous Metabolite	Inflammation/Immunology Cancer
Luteolin (Standard) is the analytical standard of Luteolin. This product is intended for research and analytical applications. Luteolin (Luteoline), a flavanoid compound, is a potent Nrf2 inhibitor. Luteolin has anti-inflammatory, anti-cancer properties, including the induction of apoptosis and cell cycle arrest, and the inhibition of metastasis and angiogenesis, in several cancer cell lines, including human non-small lung cancer cells .

Sugemalimab	PD-1/PD-L1	Cancer
Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research .

Skp2 inhibitor 2	E1/E2/E3 Enzyme	Cancer
Skp2 inhibitor 2 is a Skp2-Cks1 protein-protein interaction inhibitor with a human IC₅₀ of 0.57 μM. Skp2 inhibitor 2 binds to Skp2 at the interaction interface to block Skp2-Cks1 complex formation. Skp2 inhibitor 2 can be used for the research of gastric cancer, non-small cell lung cancer, breast cancer, prostate cancer .

Intetumumab CNTO 95; Anti-human CD51 Recombinant Antibody	Integrin Apoptosis	Cancer
Intetumumab (CNTO 95) is a human monoclonal antibody targeting αv integrin, with a K_d value of 1-24 nM. Through high-affinity binding to αv integrin, Intetumumab inhibits its interaction with extracellular matrix proteins (such as vitronectin and fibronectin), thereby blocking the downstream focal adhesion kinase signaling pathway. This further inhibits the adhesion, migration and invasion of tumor cells as well as the proliferation of vascular endothelial cells, promotes cell apoptosis, and exerts anti-tumor and anti-angiogenic effects. Intetumumab can be used in research related to head and neck cancer, non-small cell lung cancer and uterine serous papillary carcinoma .

Domvanalimab AB154	Transmembrane Glycoprotein	Cancer
Domvanalimab (AB154) is an anti-TIGIT humanized monoclonal antibody. Domvanalimab binds human TIGIT9 and blocks the TIGIT-CD155 interaction. Domvanalimab can be used for studies of non-small cell lung cancer and esophageal cancer .

Davutamig REGN-5093	c-Met/HGFR	Cancer
Davutamig (REGN-5093) is a human IgG4-kappa, anti-MET bispecific antibody. Davutamig binds 2 distinct epitopes of MET, blocking ligand binding and inducing MET internalization and degradation. Davutamig is applicable to the research of advanced non-small cell lung cancer with MET gene abnormalities .

Volrustomig MEDI-5752	PD-1/PD-L1 CTLA-4	Cancer
Volrustomig (MEDI-5752) is a human IgG1 κ monoclonal antibody targeting CTLA4/PD1. The isotype control for Volrustomig is Human IgG1 kappa, Isotype Control (HY-P99001). Volrustomig anchors to the surface of T cells by binding PD-1, induces PD-1 internalization and degradation, and preferentially inhibits CTLA-4 on activated PD-1 ⁺ T cells. Volrustomig binds to tumor-infiltrating lymphocytes and a subset of PD-1 ⁺ B cells, enhances T cell function and IFNγ secretion. Volrustomig reduces the activation of non-tumor-infiltrating lymphocytes and exhibits manageable toxicity. Volrustomig can be used in research on various cancers, such as non-small cell lung cancer, gastric cancer, hepatobiliary cancer, and cervical cancer .

Lifastuzumab	ADC Antibody Sodium Phosphate Cotransporter	Cancer
Lifastuzumab is a humanized anti-NaPi2b IgG1 monoclonal antibody. Lifastuzumab can be coupled with monomethyl auristatin E (MMAE) (HY-15162) through ADC Linker to form an antibody-drug conjugate (ADC) Lifastuzumab vedotin (HY-P99705) with anticancer activity. Lifastuzumab vedotin can be studied in research for non-small cell lung cancer and ovarian cancer. Recommend Isotype Control: Human IgG1 kappa, Isotype Control (HY-P99001) .

Ethaselen BBSKE	TrxR	Cancer
Ethaselen (BBSKE) is an orally active, selective thioredoxin reductase (TrxR) inhibitor with IC₅₀s of 0.5 and 0.35 μM for the wild-type human TrxR1 and rat TrxR1, respectively. Ethaselen specifically binds to the unique selenocysteine-cysteine redox pair in the C-terminal active site of mammalian TrxR1. Ethaselen, an organoselenium compound, is a potent antitumor candidate that exerts potent inhibition on non-small cell lung cancer (NSCLC) by targeting TrxR .

Dalmelitinib	c-Met/HGFR	Cancer
Dalmelitinib is an orally active selective c-Met kinase inhibitor (IC₅₀: 2.9 nM) that binds to the ATP-binding region of c-Met. Dalmelitinib induces the phosphorylation of MET, partially or completely inhibits the phosphorylation of AKT and ERK. Dalmelitinib potently inhibits cancer cell (c-Met oncogene amplification) proliferation, and is used for the research of cancers like human non-small cell lung cancer (NSCLC) .

SMD-3236	PROTACs SWI/SNF Complex Epigenetic Reader Domain	Cancer
SMD-3236 is a SMARCA2 PROTAC degrader with a DC₅₀ of 0.5 nM, a D_max of 98%, and an IC₅₀ of 42.2 nM against human SMARCA2. SMD-3236 induces proteasome- and ubiquitin-like modification-dependent degradation of SMARCA2 protein by binding to SMARCA2 and VHL-1. SMD-3236 inhibits the growth of SMARCA4-deficient cancer cells. SMD-3236 induces significant and persistent depletion of SMARCA2 in tumor tissues. SMD-3236 suppresses tumor growth in SMARCA4-deficient human cancer xenograft models. SMD-3236 can be used in research related to SMARCA4-deficient cancers such as melanoma, non-small cell lung cancer, and acute myeloid leukemia .

JP-11646	Pim Caspase Apoptosis Necroptosis PARP NF-κB	Cancer
JP-11646 is a pan-PIM inhibitor with increased potency against PIM2 (IC₅₀ = 0.5 nM). JP11646 is freely reversible and ATP non-competitive. JP-11646 results in a decrease of PIM1, 2, and 3 mRNA. JP-11646 can effectively inhibit cell viability in small cell lung cancer (SCLC) and large cell neuroendocrine carcinomas of the lung (LCNEC). JP-11646 can cause a decrease in p-4EBP-1 protein, increasing the cleavage of caspases while decreasing caspase-3. JP-11646 induces apoptosis or necroptosis in cells. JP-11646 leads to reductions in MYC paralogs. JP-11646 can be used for the study of SCLC, LCNEC, human acute leukemia (AML), multiple myeloma (MM), and triple-negative breast cancer (TNBC) .

Metralindole hydrochloride	CDK	Cancer
Metralindole hydrochloride is an inhibitor of human cyclin-dependent kinase CDK2 and human protein kinase CK2 holoenzyme. Metralindole hydrochloride shows good potential as a non-small cell lung cancer inhibitor .

Luteolin monohydrate 85+ Cited Publications	Keap1-Nrf2 Apoptosis Autophagy Endogenous Metabolite	Others Cancer
Luteolin (monohydrate) is the monohydrate of Luteolin. Luteolin (Luteoline), a flavonoid, is also a potent Nrf2 inhibitor. Luteolin has anti-inflammatory and anticancer properties, induces apoptosis and cell cycle arrest in multiple human cancer cell lines, including non-small lung cancer cells, and inhibits cell metastasis and angiogenesis .

Zimberelimab GLS-010; AB-122; WBP-3055	PD-1/PD-L1	Cancer
Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1 monoclonal antibody with an EC₅₀ of 210 pM for human PD-1. Zimberelimab effectively blocks the binding of PD-L1 and PD-L2 to cell-surface PD-1 in CHO-S cells, with IC₅₀ values of 580 pM and 670 pM, respectively. Zimberelimab shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma .

Atigotatug BMS-986012	Transmembrane Glycoprotein	Cancer
Atigotatug (BMS-986012) is a fully human IgG1 antibody binds specifically to FucGM1 with an EC₅₀ of 0.15 nmol/L for FucGM1. Atigotatug is a FcγRIIIa ligand with a K_d of 21 nmol/L. Atigotatug demonstrates antitumor efficacy in multiple mouse small cell lung cancer models .

Adenosine-3',5'-bisphosphate	Small Interfering RNA (siRNA)	Cancer
Adenosine-3',5'-bisphosphate is an exoribonuclease XRN1 inhibitor with an IC₅₀ of 36 nM, a K_D of 12 nM, and a K_D of 14 nM against human XRN2. Adenosine-3',5'-bisphosphate binds to the bimetallic active site of human XRN1, and also binds potently to human XRN2 via its conserved bimetallic active site. Adenosine-3',5'-bisphosphate can be used in research related to non-small cell lung cancer .

NGM-438	TNF Receptor	Cancer
NGM-438 is a humanized monoclonal antibody antagonist of LAIR1, with a K_a of 0.26 nM for human LAIR1 and 4.28 nM for cynomolgus monkey LAIR1. NGM-438 blocks the binding of LAIR1 to its Collagen ligand and antagonizes the Collagen-induced LAIR1 signaling pathway. NGM-438 reverses FcγR signaling inhibition in myeloid cells, induces dendritic cells to secrete TNFα, promotes T cell proliferation, and triggers myeloid inflammation and allogeneic T cell responses. NGM-438 sensitizes refractory mouse lung cancer to PD-1 blockade, increases the content of intratumoral CD8 ⁺ T cells and the expression of inflammatory genes. NGM-438 is applicable to research related to solid tumors, refractory solid tumors and non-small cell lung cancer .

Lupartumab Amadotin BAY 1129980; Anti-C4.4a antibody-drug conjugates	Antibody-Drug Conjugates (ADCs)	Cancer
Lupartumab Amadotin (BAY 1129980) is an antibody–drug conjugate (ADC) consisting of a fully human C4.4A (LYPD3)-targeting mAb (BAY 1135626) (HY-147281) conjugated to a novel, highly potent derivative of the microtubule-disrupting cytotoxic drug auristatin via a noncleavable alkyl hydrazide linker. Lupartumab Amadotin can be used for the research of non-small cell lung cancer .

LAF389	MetAP Drug Intermediate	Cancer
LAF389, a prodrug of LAF153 (HY-183876), is a methionine aminopeptidase (MetAps) inhibitor with an IC₅₀ of 800 nM against MetAp2, and exhibits a maximum inhibition rate of 20% against MetAp1 at 300 nM. LAF389 possesses antiproliferative, antiangiogenic and cytotoxic activities. LAF389 can be used in research related to cancers such as advanced solid tumors .

FTO-IN-7	Fat Mass and Obesity-associated Protein (FTO)	Cancer
FTO-IN-7 (compound 17) is an inhibitor of FTO (fat mass and obesity-associated protein) with an IC₅₀ of <1 μM. FTO-IN-7 can be used for the study of small-cell lung cancers and human bone marrow striated muscle cancer .

Vulinacimab HLX-06	VEGFR	Cancer
Vulinacimab (HLX-06) is a human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2). Vulinacimab specifically binds to and inhibits VEGFR-2, which may inhibit tumor angiogenesis and tumor cell proliferation. Vulinacimab can be used for the research of solid tumors and non-small cell lung cancer .

CEP-28122 mesylate salt	Anaplastic lymphoma kinase (ALK)	Cancer
CEP-28122 mesylate salt, a diaminopyrimidine derivative, is a potent, selective, and orally active ALK inhibitor with an IC₅₀ value of 1.9 nM. CEP-28122 mesylate salt has antitumor activity in experimental models of ALK-positive human cancers. CEP-28122 mesylate salt has good pharmacodynamic and pharmacokinetic activity. CEP-28122 mesylate salt can be used for the study of ALK-positive anaplastic large-cell lymphoma (ALCL), non-small cell lung cancer (NSCLC), and neuroblastoma cells .

CEP-28122	Anaplastic lymphoma kinase (ALK)	Cancer
CEP-28122, a diaminopyrimidine derivative, is a potent, selective, and orally active ALK inhibitor with an IC₅₀ value of 1.9 nM. CEP-28122 has antitumor activity in experimental models of ALK-positive human cancers. CEP-28122 has good pharmacodynamic and pharmacokinetic activity. CEP-28122 can be used for the study of ALK-positive anaplastic large-cell lymphoma (ALCL), non-small cell lung cancer (NSCLC), and neuroblastoma cells .

XR5944	Endogenous Metabolite	Cancer
XR5944 is an anti-tumor compound with DNA-targeting activity. As a topoisomerase inhibitor, XR5944 can effectively inhibit the activities of topoisomerase I and II. XR5944 shows excellent anti-tumor activity against human and mouse tumor cells in vitro and in vivo. XR5944 exhibits significant potency in multiple cell lines, with IC₅₀ values of 0.04-0.4 nM. XR5944 is not affected by atypical drug resistance in cells and remains significantly active even in cells overexpressing P-glycoprotein or multidrug resistance-related proteins. XR5944 showed anti-tumor efficacy in human tumor models of H69 small cell lung cancer and HT29 colon cancer, inducing tumor regression in most animals in the HT29 model. XR5944 can be used to study biological processes related to colon and lung cancer .

MEDI0639 21H3RK	Notch	Cancer
MEDI0639 (21H3RK) is a human monoclonal antibody (mAb) targeting DLL4. MEDI0639 inhibits Notch1 binding to Dll4. MEDI0639 reverses Notch1-mediated growth inhibition of human umbilical vein endothelial cells in vitro. MEDI0639 promotes human angiogenesis and reduces the number of vessels covered by smooth muscle actin-positive mural cells. MEDI0639 can be used in Small cell lung cancer and solid tumors research .

Prostaglandin F2α serinol amide	Prostaglandin Receptor	Endocrinology
Prostaglandin F2α serinol amide is a serinolamide G protein-coupled receptor that increases calcium levels in human non-small cell lung cancer cells. Prostaglandin F2α is also a luteinizing hormone in sheep and may be a nociceptive mediator in the spinal cord .

(E)-3-Chloroacrylic acid	Drug Intermediate	Cancer
(E)-3-Chloroacrylic acid is an intermediate. (E)-3-Chloroacrylic acid can be used in the synthesis of Compound 81. (E)-3-Chloroacrylic acid can be used in research on human non-small cell lung cancer with KRAS G12C mutation . (E)-3-Chloroacrylic acid is a substrate of trans-3-chloroacrylic acid dehalogenase (Km = 34 µM) .

Imneskibart AU-007; BD-8; BDG8	Interleukin Related	Cardiovascular Disease Inflammation/Immunology Cancer
Imneskibart (AU-007) is a human monoclonal antibody that binds to the CD25-binding epitope of interleukin-2 (IL-2), blocking the binding of IL-2 to the trimeric IL-2 receptor while retaining the ability to bind to the dimeric IL-2 receptor. Imneskibart expands effector T cell and NK cell populations, reduces regulatory T cells, increases the effector T cell/regulatory T cell ratio, and alleviates vascular leakage. Imneskibart can be used in research related to melanoma and non-small cell lung cancer. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001) .

NK224	PD-1/PD-L1	Cancer
NK224 is a peptide-based radiotracer targeting human PD-L1, with dual-radionuclide ( ⁶⁸Ga and ¹⁸F) labeling compatibility enabled by the NOTA chelator. NK224 exhibits high binding affinity to PD-L1, with an IC₅₀ value of 2.45 nM. NK224 visualizes intrapatient tumor heterogeneity and dynamically monitors PD-L1 target occupancy during immunotherapy. NK224 can be used for the study of non-small cell lung cancer (NSCLC) .

Cat. No.	Product Name	Type

HY-141598

Datopotamab deruxtecan (solution)

2 Publications Verification

DS-1062 (solution); Dato-DXd (solution)

Fluorescent Dyes

Datopotamab deruxtecan (DS-1062) solution is a TROP2-targeted antibody-drug conjugate (ADC) with human TROP2 K_d of 0.74 nmol/L. Datopotamab deruxtecan solution consists of the antibody Datopotamab (HY-P99843) and the toxic molecule-linker conjugate Deruxtecan (HY-13631E). Datopotamab deruxtecan solution binds TROP2, triggers internalization and lysosomal trafficking and releases DXd topoisomerase I inhibitor payload. Datopotamab deruxtecan solution disrupts DNA function, induces DNA damage, apoptosis, and bystander killing of tumor microenvironment cells. Datopotamab deruxtecan solution can be used in research related to triple-negative breast cancer, gastric cancer, and non-small cell lung cancer .

HY-164729

FZ-AD005

Fluorescent Dyes

FZ-AD005 is a DLL3-targeting antibody-drug conjugate (ADC) with high selectivity, composed of the anti-DLL3 antibody FZ-A038 (HY-P990896), a dipeptide linker (Val-Ala), and DXd (HY-13631D). The K_d value of FZ-AD005 for human DLL3 ranges from 13.29 to 58.3 pmol/L. After binding to DLL3 on the cell surface, FZ-AD005 mediates endocytosis, and the payload DXd is released via cleavage by lysosomal cathepsins. DXd inhibits topoisomerase TopI to induce double-strand DNA breaks, cell cycle arrest and apoptosis, and FZ-AD005 exhibits bystander killing activity against adjacent DLL3-negative cells. FZ-AD005 shows stable circulation in vivo, has good tolerance and acceptable pharmacokinetic profiles in rats and cynomolgus monkeys, and effectively inhibits the growth of DLL3-expressing tumor cells. FZ-AD005 serves as a promising candidate molecule for research on small cell lung cancer and human neuroendocrine prostate cancer .

HY-12299G

WH-4-023

Dual LCK/SRC inhibitor

Fluorescent Dyes

WH-4-023 GMP is WH-4-023 (HY-12299) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. WH-4-023 (Dual LCK/SRC inhibitor) is a Lck/Src dual target inhibitor with functions in stem cell maintenance and differentiation regulation. WH-4-023 blocks epithelial-mesenchymal transition, supports the self-renewal of porcine embryonic stem cells, and inhibits their differentiation into mesoderm and endoderm. WH-4-023 is a key component of 3i/LAF medium, and enables the stable establishment and long-term maintenance of porcine pre-gastrulation epiblast stem cell lines. Removal of WH-4-023 reduces the expression of pluripotency factors in porcine and human extended pluripotent stem cells. WH-4-023 can be applied to relevant studies such as non-small cell lung cancer resistant to EGFR-TKIs .

Cat. No.	Product Name	Type

HY-12299G

WH-4-023

Dual LCK/SRC inhibitor

Biochemical Assay Reagents

Cat. No.	Product Name	Target	Research Area

HY-P10978

NK224	PD-1/PD-L1	Cancer
NK224 is a peptide-based radiotracer targeting human PD-L1, with dual-radionuclide ( ⁶⁸Ga and ¹⁸F) labeling compatibility enabled by the NOTA chelator. NK224 exhibits high binding affinity to PD-L1, with an IC₅₀ value of 2.45 nM. NK224 visualizes intrapatient tumor heterogeneity and dynamically monitors PD-L1 target occupancy during immunotherapy. NK224 can be used for the study of non-small cell lung cancer (NSCLC) .

Cat. No.	Product Name

HY-K6103

Human Small Cell Lung Cancer Organoid Kit
MCE Human Small Cell Lung Cancer Organoid Kit contains Small Cell Lung Cancer Organoid Basal Medium A, Small Cell Lung Cancer Organoid Supplement B (50×),Small Cell Lung Cancer Organoid Supplement C (250×). This product can be used to efficiently construct human small cell lung cancer organoid.

Cat. No.	Product Name	Target	Research Area	Image

HY-P9903

Nivolumab Maximum Cited Publications 23 Publications Verification BMS-936558; ONO-4538; MDX-1106	PD-1/PD-L1	Infection Cancer
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

HY-P99575

Tarlatamab 1 Publications Verification AMG-757	Notch	Inflammation/Immunology Cancer
Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the K_Ds of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the K_Ds of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research .

HY-P99275

Patritumab 1 Publications Verification AMG-888; U3-1287	EGFR Akt ERK PARP Survivin	Cancer
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .

HY-P9964

Necitumumab 11F8; IMC-11F8; LY3012211	EGFR	Cancer
Necitumumab (11F8; IMC-11F8; LY3012211) is a human IgG monoclonal antibody directed against EGFR. Necitumumab binds to the EGF binding site of EGFR, blocks ligand binding, neutralizes ligand-induced EGFR phosphorylation and downstream signaling, induces EGFR internalization and degradation, and mediates antibody-dependent cellular cytotoxicity (ADCC) in EGFR-expressing cells. Necitumumab enhances antitumour activity in combination with Gemcitabine (HY-17026) and Cisplatin (HY-17394) in murine non-small-cell lung cancer xenograft models. Necitumumab can be used in research on cancers such as non-small cell lung cancer and colorectal cancer .

HY-P990932

Obrixtamig BI 764532; OBT 620	CD3	Cancer
Obrixtamig (BI 764532; OBT 620) is an CD3E/DLL3-targeting L-κ-G1-h-CH2-CH3_L-λ-G1-h-CH2-CH3 type human antibody. Obrixtamig is a delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager. Obrixtamig can be used for research of DLL3-positive small cell lung cancer .

HY-P99279

Bavituximab 1 Publications Verification Anti-human Phosphatidylserine Recombinant Antibody; PGN-401; CH3G4	Inhibitory Antibodies	Cancer
Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a phosphatidylserine (PS)-targeting monoclonal antibody, suppresses tumor growth by targeting tumor vasculature and reactivating antitumor immunity. Bavituximab plus Paclitaxel (HY-B0015) and Carboplatin (HY-17393), have enhanced inhibition on non-small-cell lung cancer .

HY-P99189

Cixutumumab IMC-A12; NSC742460	IGF-1R	Cancer
Cixutumumab (IMC-A12) is a human anti-IGF-1R monoclonal antibody with high affinity that inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab also mediates the internalization and degradation of IGF-IR. Cixutumumab shows broad-spectrum anti-tumour activity and can be used in studies of cancers such as lung cancer, malignancies, leukaemia, non-small cell lung cancer and prostate cancer .

HY-P99114

Sugemalimab	PD-1/PD-L1	Cancer
Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research .

HY-P99296

Intetumumab CNTO 95; Anti-human CD51 Recombinant Antibody	Integrin Apoptosis	Cancer
Intetumumab (CNTO 95) is a human monoclonal antibody targeting αv integrin, with a K_d value of 1-24 nM. Through high-affinity binding to αv integrin, Intetumumab inhibits its interaction with extracellular matrix proteins (such as vitronectin and fibronectin), thereby blocking the downstream focal adhesion kinase signaling pathway. This further inhibits the adhesion, migration and invasion of tumor cells as well as the proliferation of vascular endothelial cells, promotes cell apoptosis, and exerts anti-tumor and anti-angiogenic effects. Intetumumab can be used in research related to head and neck cancer, non-small cell lung cancer and uterine serous papillary carcinoma .

HY-P99858

Domvanalimab AB154	Transmembrane Glycoprotein	Cancer
Domvanalimab (AB154) is an anti-TIGIT humanized monoclonal antibody. Domvanalimab binds human TIGIT9 and blocks the TIGIT-CD155 interaction. Domvanalimab can be used for studies of non-small cell lung cancer and esophageal cancer .

HY-P990073

Davutamig REGN-5093	c-Met/HGFR	Cancer
Davutamig (REGN-5093) is a human IgG4-kappa, anti-MET bispecific antibody. Davutamig binds 2 distinct epitopes of MET, blocking ligand binding and inducing MET internalization and degradation. Davutamig is applicable to the research of advanced non-small cell lung cancer with MET gene abnormalities .

HY-P990690

Volrustomig MEDI-5752	PD-1/PD-L1 CTLA-4	Cancer
Volrustomig (MEDI-5752) is a human IgG1 κ monoclonal antibody targeting CTLA4/PD1. The isotype control for Volrustomig is Human IgG1 kappa, Isotype Control (HY-P99001). Volrustomig anchors to the surface of T cells by binding PD-1, induces PD-1 internalization and degradation, and preferentially inhibits CTLA-4 on activated PD-1 ⁺ T cells. Volrustomig binds to tumor-infiltrating lymphocytes and a subset of PD-1 ⁺ B cells, enhances T cell function and IFNγ secretion. Volrustomig reduces the activation of non-tumor-infiltrating lymphocytes and exhibits manageable toxicity. Volrustomig can be used in research on various cancers, such as non-small cell lung cancer, gastric cancer, hepatobiliary cancer, and cervical cancer .

HY-P99970

Lifastuzumab	ADC Antibody Sodium Phosphate Cotransporter	Cancer
Lifastuzumab is a humanized anti-NaPi2b IgG1 monoclonal antibody. Lifastuzumab can be coupled with monomethyl auristatin E (MMAE) (HY-15162) through ADC Linker to form an antibody-drug conjugate (ADC) Lifastuzumab vedotin (HY-P99705) with anticancer activity. Lifastuzumab vedotin can be studied in research for non-small cell lung cancer and ovarian cancer. Recommend Isotype Control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P99109

Zimberelimab GLS-010; AB-122; WBP-3055	PD-1/PD-L1	Cancer
Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1 monoclonal antibody with an EC₅₀ of 210 pM for human PD-1. Zimberelimab effectively blocks the binding of PD-L1 and PD-L2 to cell-surface PD-1 in CHO-S cells, with IC₅₀ values of 580 pM and 670 pM, respectively. Zimberelimab shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma .

HY-P990902

Atigotatug BMS-986012	Transmembrane Glycoprotein	Cancer
Atigotatug (BMS-986012) is a fully human IgG1 antibody binds specifically to FucGM1 with an EC₅₀ of 0.15 nmol/L for FucGM1. Atigotatug is a FcγRIIIa ligand with a K_d of 21 nmol/L. Atigotatug demonstrates antitumor efficacy in multiple mouse small cell lung cancer models .

HY-P991193

NGM-438	TNF Receptor	Cancer
NGM-438 is a humanized monoclonal antibody antagonist of LAIR1, with a K_a of 0.26 nM for human LAIR1 and 4.28 nM for cynomolgus monkey LAIR1. NGM-438 blocks the binding of LAIR1 to its Collagen ligand and antagonizes the Collagen-induced LAIR1 signaling pathway. NGM-438 reverses FcγR signaling inhibition in myeloid cells, induces dendritic cells to secrete TNFα, promotes T cell proliferation, and triggers myeloid inflammation and allogeneic T cell responses. NGM-438 sensitizes refractory mouse lung cancer to PD-1 blockade, increases the content of intratumoral CD8 ⁺ T cells and the expression of inflammatory genes. NGM-438 is applicable to research related to solid tumors, refractory solid tumors and non-small cell lung cancer .

HY-P990947

Tilatamig AZD9592 Antibody	ADC Antibody EGFR	Cancer
Tilatamig (AZD9592 Antibody) is a human antibody of the Ig (G1-κ_G1-λ2) subtype that targets EGFR/MET. Tilatamig conjugates with the Top1 inhibitor AZ14170133 (HY-145399) to form the antibody-drug conjugate (ADC) Tilatamig samrotecan (HY-171124) (AZD9592). Tilatamig accurately targets NSCLC models including EGFR-mutant, EGFR-wildtype, and EGFR tyrosine kinase inhibitor-treated ones, and its activity correlates with high expression of EGFR, c-MET and SLFN11. Tilatamig is available for in vivo anti-tumor studies in patient-derived xenograft models of non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) .

HY-P99516

Vulinacimab HLX-06	VEGFR	Cancer
Vulinacimab (HLX-06) is a human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2). Vulinacimab specifically binds to and inhibits VEGFR-2, which may inhibit tumor angiogenesis and tumor cell proliferation. Vulinacimab can be used for the research of solid tumors and non-small cell lung cancer .

HY-P991423

MEDI0639 21H3RK	Notch	Cancer
MEDI0639 (21H3RK) is a human monoclonal antibody (mAb) targeting DLL4. MEDI0639 inhibits Notch1 binding to Dll4. MEDI0639 reverses Notch1-mediated growth inhibition of human umbilical vein endothelial cells in vitro. MEDI0639 promotes human angiogenesis and reduces the number of vessels covered by smooth muscle actin-positive mural cells. MEDI0639 can be used in Small cell lung cancer and solid tumors research .

HY-P991000

Imneskibart AU-007; BD-8; BDG8	Interleukin Related	Cardiovascular Disease Inflammation/Immunology Cancer
Imneskibart (AU-007) is a human monoclonal antibody that binds to the CD25-binding epitope of interleukin-2 (IL-2), blocking the binding of IL-2 to the trimeric IL-2 receptor while retaining the ability to bind to the dimeric IL-2 receptor. Imneskibart expands effector T cell and NK cell populations, reduces regulatory T cells, increases the effector T cell/regulatory T cell ratio, and alleviates vascular leakage. Imneskibart can be used in research related to melanoma and non-small cell lung cancer. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P991058

Zimistobart BMS-986315	Checkpoint Kinase (Chk)	Cancer
Zimistobart (BMS-986315) is a fully human IgG1 antibody that targets NKG2A. Zimistobart can be used for the study of non-small cell lung cancer (NSCLC). The isotype control for Zimistobart can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P991397

Sym023	Tim3	Cancer
Sym023 is a human monoclonal antibody (mAb) targeting TIM-3/HAVCR2/CD366. Sym023 enhances immunostimulatory and anti-tumor activities. Sym023 can be used in Non-small cell lung cancer, Solid tumors and Lymphoma research .

HY-P991738

LM-299	PD-1/PD-L1 VEGFR	Cancer
LM-299 is a PD-1/VEGF bispecific antibody. LM-299 achieves its dual binding activity through the effective binding of the anti-VEGF-A antibody at the fab end to human VEGF-A, coupled with the blockade of the PD-1/PD-L1 pathway by the anti-PD-1 antibody at the-Fc end. LM-299 can be used for the study of non-small cell lung cancer (NSCLC).

HY-P991378

MORAb-066	Transmembrane Glycoprotein	Cancer
MORAb-066 is a human monoclonal antibody (mAb) targeting CD142/F3/TF. MORAb-066 can be used in Breast cancer, Colorectal cancer, Non-small cell lung cancer and Pancreatic cancer research .

HY-P991173

AMG-119	Notch	Cancer
AMG-119 is a humanized IgG1 monoclonal antibody that targets delta-like ligand 3 (DLL3). AMG-119 can be used for the study of relapsed/refractory (R/R) small cell lung cancer (SCLC). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P991458

hu3S193	Transmembrane Glycoprotein	Cancer
hu3S193 is a human IgG monoclonal antibody (mAb) targeting Lewis Y. hu3S193 has excellent immune effector function (complement-dependent cytotoxicity) (IC₅₀: 1.0 μg/ml) and antibody-dependent cellular cytotoxicity (IC₅₀: 5.0 μg/ml). hu3S193 can be used in small cell lung cancer (SCLC) research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P991883

Metuzumab Licartin; Metuximab; Mehuzumab	Apoptosis CDK Caspase Bcl-2 Family	Cancer
Metuzumab (Licartin) is a human-mouse chimeric IgG1 monoclonal antibody targeting CD147. Metuzumab induces Apoptosis, reduces levels of Cyclin D1, full-length Caspase-3, and Bcl-2, and increases Bax expression. Metuzumab enhances the sensitivity of non-small cell lung cancer (NSCLC) cells to Gemcitabine (HY-17026). Metuzumab is applicable for research on hepatocellular carcinoma and non-small cell lung cancer [1] [2]_.

HY-P992317

ATL301	Inhibitory Antibodies	Inflammation/Immunology Cancer
ATL301 is a human monoclonal antibody that targets human ganglioside GD2 (ganglioside GD2). GD2 is a highly expressed glycolipid antigen on the surface of neuroepithelial tumor cells, and is commonly found in neuroblastoma, melanoma, osteosarcoma, small cell lung cancer, etc.

HY-P992146

Zevontabart MYTX-011 Antibody; Q-397	ADC Antibody c-Met/HGFR	Cancer
Zevontabart (MYTX-011 Antibody; Q-397) is a pH-dependent anti-c-MET antibody. Zevontabart regulates the trafficking process of c-MET to reduce receptor recycling, and enhances its own endocytosis and accumulation in c-MET-expressing cells. Zevontabart induces cytotoxicity in solid tumor cells and exerts anti-tumor activity in a non-small cell lung cancer xenograft mouse model. Zevontabart can be used to synthesize ADC, such as: MYTX-011. Zevontabart can be used in studies related to non-small cell lung cancer, with its corresponding isotype control being Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P992347

DS-5573a	CD276/B7-H3	Cancer
DS-5573a is a human monoclonal antibody targeting B7-H3, with a K_d of 1.8 nM for the 4Ig isoform and 11 nM for the 2Ig isoform. DS-5573a induces antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis against B7-H3-expressing cancer cells. DS-5573a exerts dose-dependent anti-tumor activity via effector cells. DS-5573a can be used in the research of cancers including breast adenocarcinoma, non-small cell lung cancer, renal cell adenocarcinoma, gastric cancer and prostate cancer .

HY-P992395

JNJ-64164711 JNJ-711	TNF Receptor NF-κB	Cancer
JNJ-64164711 (JNJ-711) is a bifunctional antibody that simultaneously targets human GITR/TNFRSF18 and FcγRIIIa. JNJ-64164711 binds to the GITR domain to activate the NF-κB signaling pathway, while binding to FcγRIIIa to support antibody-dependent cellular cytotoxicity (ADCC). JNJ-64164711 can specifically eliminate GITR-positive hematological tumor cells, activated T cells and intratumoral regulatory T cells through the ADCC mechanism, thereby significantly enhancing the body's anti-tumor immune response. JNJ-64164711 can be used in research related to non-small cell lung cancer, colorectal cancer, prostate cancer, renal cell carcinoma and hematological tumors .

HY-P991954

GT103	Complement System Syk	Inflammation/Immunology Cancer
GT103 is a human-derived monoclonal antibody targeting complement factor H (CFH). GT103 binds to a conformationally distinct epitope of CFH on tumor cells. GT103 activates the classical complement pathway, induces complement-dependent cytotoxicity, and triggers antibody-dependent cellular phagocytosis (ADCP) of tumor cells. GT103 increases calreticulin translocation to tumor cell plasma membranes. GT103 mediates B-cell activation via Syk kinase phosphorylation. GT103 inhibits tumor growth and metastasis in animal models. GT103 can be used for the research of non-small cell lung cancer .

HY-P992369

HMBD-002	VISTA	Cancer
HMBD-002 is an Fc-independent, non-depleting IgG4 subclass antibody that targets VISTA and VSIG3. It is widely used in research related to various solid tumors, including colon cancer, triple-negative breast cancer, and non-small cell lung cancer. HMBD-002 blocks the interactions of VISTA with VSIG3 and LRIG1, relieves immunosuppression without depleting VISTA-positive cells, activates the cytotoxic program of CD8 ⁺ T cells, and drives the type I interferon signaling pathway. HMBD-002 reprograms tumor-associated macrophages to the M1 phenotype, reduces tumor infiltration of inhibitory myeloid cells, thereby significantly inhibiting tumor growth and improving survival. HMBD-002 is well tolerated in rodent and non-human primate animal models .

HY-P992396

KTN0073	c-Met/HGFR	Cancer
KTN0073 is a high-affinity MET receptor tyrosine kinase inhibitor. KTN0073 can be used in studies related to non-small cell lung cancer and human cancers driven by HGF, MET amplification, or exon 14 mutation. KTN0073 binds to the Sema/PSI domain to block the HGF-MET interaction, and induces ubiquitination and degradation of oncogenic MET receptors via an HGF-independent pathway, thereby inhibiting MET-dependent signal transduction. KTN0073 exhibits significant antitumor activity in vivo, and its tumor suppressive activity is superior to that of the IgG1 subtype when grafted to the IgG2 constant region .

Cat. No.	Product Name		Classification

HY-50896

Erlotinib 130+ Cited Publications CP-358774; NSC 718781; OSI-774		Alkynes
Erlotinib (CP-358774) is a directly acting EGFR tyrosine kinase inhibitor, with an IC₅₀ of 2 nM for human EGFR. Erlotinib reduces EGFR autophosphorylation in intact tumor cells with an IC₅₀ of 20 nM. Erlotinib is used for the treatment of non-small cell lung cancer . Erlotinib is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Cat. No.	Product Name		Classification

HY-148511

Vidutolimod CMP-001		CpG ODNs
Vidutolimod (CMP-001) is a virus-like particle containing a TLR9 activator . Vidutolimod induces human peripheral blood mononuclear cells to secrete IFNα, and upregulates the gene expression of CXCL10, PDL1, IDO and CD80. Vidutolimod activates TLR9, which in turn triggers plasmacytoid dendritic cell activation, production of IFNγ and TNFα, induction of CXCL10, and recruitment of antitumor T cells. Vidutolimod causes influenza-like symptoms, hypotension and tumor regression, and its activity depends on the presence of anti-Qβ antibodies. Vidutolimod modulates monocyte function, promotes CD4 T cell proliferation, and activates multiple immune cell types in an environment with anti-Qβ antibodies. Vidutolimod prolongs the survival of tumor-bearing mice. Vidutolimod is used in research related to advanced melanoma, head and neck squamous cell carcinoma, and advanced non-small cell lung cancer .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

human small cell lung cancer

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

MCE Kits

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

GMP Molecules

Natural
Products